NEWS & EVENTS
NIBIB-funded bioengineers at the Massachusetts Institute of Technology demonstrated the role of geometry in the function of biomedical implants. The group implanted capsules carrying insulin-producing cells into a diabetic mouse model demonstrating that increased capsule size significantly reduced the immune response to the capsule allowing it to function five times longer than a more conventional, smaller capsule. Read more at MIT News.
NIBIB-funded researchers have designed a nanoparticle-based treatment that inhibits breast cancer metastasis in a mouse model. The nanoparticle carries an siRNA that silences the gene for Beta-3 integrin--a protein that is responsible for the metastasis of breast cancer to other sites in the body. The research team developed the system for difficult-to-treat triple-negative breast cancer and hope to move their experiments from animal models to clinical trials. Read more at ScienceDaily.
The Wall Street Journal reports on a novel method for regenerating a meniscus, the pad that serves as a shock absorber between the thigh and shin bones. The technique, developed with funding support from NIBIB, uses a 3D printer to make a scaffold of a person's meniscus using a biodegradable material. The scaffold is then filled with growth factors that coax stem cells to grow a new meniscus inside the joint. The technique was recently successfully tested in sheep. Read more at www.wsj.com.
Scientists have developed and combined new paper and flexible polymer substrates with special sensing devices for rapid and accurate detection of pathogens such as HIV, as well as other biotargets. These novel technologies offer the type of robust, simple, and inexpensive biosensing systems required to provide point-of-care health care in remote areas, where there is minimal diagnostic infrastructure or equipment and a lack of trained medical technicians.
NIBIB-funded scientists joined with nearly 300 international researchers to identify gene variants that determine genetic processes and may underlie neuropsychiatric diseases. The study combined the analysis of genetic data from over 190 institutes with MRI scans from more than 30,000 individuals. Read more at MedicalXpress news.
NIBIB-funded researchers have partnered with a collaborative group to develop a new generation of anti-viral treatments. The group reports the development of a compound that drives HIV to lethal mutagenesis. The strategy takes advantage of HIV's already high mutation rate by forcing it above an intolerable threshold where the virus acquires so many mutations that it breaks down and can no longer replicate. Read more at UChicago News.